Combining Photothermal‐Photodynamic Therapy Mediated by Nanomaterials with Immune Checkpoint Blockade for Metastatic Cancer Treatment and Creation of Immune Memory
Source abstract
Abstract
Abstract The pursuit of effective treatments for metastatic cancer is still one of the most intensive areas of research in the biomedical field. In a not‐so‐distant past, the scientific community has witnessed the rise of immunotherapy based on immune checkpoint inhibitors (ICIs). This therapeutic modality intends to abolish immunosuppressive interactions, re‐establishing T cell responses against metastasized cancer cells. Despite the initial enthusiasm, the ICIs were later found to be associated with low clinical therapeutic outcomes and immune‐related side effects. To address these limitations, researchers are exploring the combination of ICIs with nanomaterial‐mediated phototherapies. These nanomaterials can accumulate within the tumor and produce, upon interaction with light, a temperature increase (photothermal therapy) and/or reactive oxygen species (photodynamic therapy), causing damage to cancer cells. Importantly, these photothermal‐photodynamic effects can pave the way for an enhanced ICI‐based immunotherapy by inducing the release of tumor‐associated antigens and danger‐associated molecular patterns, as well as by relieving tumor hypoxia and triggering a pro‐inflammatory response. This progress report analyses the potential of nanomaterial‐mediated photothermal‐photodynamic therapy in combination with ICIs, focusing on their ability to modulate T cell populations leading to an anti‐metastatic abscopal effect and on their capacity to generate immune memory that prevents tumor recurrence.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CICS‐UBI—Centro de Investigação em Ciências da Saúde Universidade da Beira Interior Covilhã 6200‐506 Portugal
Departamento de Química Universidade da Beira Interior Covilhã 6201‐001 Portugal
CIEPQPF—Departamento de Engenharia Química Universidade de Coimbra Coimbra 3030‐790 Portugal
Funding
European Regional Development Fund · Fundação para a Ciência e a Tecnologia
References (100+)
Show source-provided references
1. 10.1016/j.apsb.2015.07.00510.1016/j.apsb.2015.07.005 ↗
2. 10.1007/s00018-016-2210-510.1007/s00018-016-2210-5 ↗
3. 10.1634/theoncologist.2017-064810.1634/theoncologist.2017-0648 ↗
4. 10.1038/s41467-019-11730-810.1038/s41467-019-11730-8 ↗
5. 10.1021/acsnano.7b0473610.1021/acsnano.7b04736 ↗
6. 10.1089/jir.2018.001910.1089/jir.2018.0019 ↗
7. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
8. 10.1016/j.jconrel.2018.10.00810.1016/j.jconrel.2018.10.008 ↗
9. Webb E. S. · J. Biomed. Res. · 2018 · 32 · 31710.7555/JBR.31.20160168 ↗
10. 10.3390/cancers1203073810.3390/cancers12030738 ↗
11. 10.1016/j.intimp.2018.06.00110.1016/j.intimp.2018.06.001 ↗
12. 10.1038/s41467-020-17670-y10.1038/s41467-020-17670-y ↗
13. 10.3389/fimmu.2018.0181610.3389/fimmu.2018.01816 ↗
14. 10.1186/s13045-018-0644-y10.1186/s13045-018-0644-y ↗
15. 10.1186/s40425-018-0442-710.1186/s40425-018-0442-7 ↗
16. 10.14740/jocmr375010.14740/jocmr3750 ↗
17. 10.1038/s41571-019-0218-010.1038/s41571-019-0218-0 ↗
18. 10.1038/bjc.2017.43410.1038/bjc.2017.434 ↗
19. 10.1200/EDBK_24083710.1200/EDBK_240837 ↗
20. 10.1016/j.immuni.2018.03.00710.1016/j.immuni.2018.03.007 ↗
21. 10.3389/fimmu.2020.0190610.3389/fimmu.2020.01906 ↗
22. 10.1038/s41590-020-00834-910.1038/s41590-020-00834-9 ↗
23. 10.1016/j.ccell.2020.07.00410.1016/j.ccell.2020.07.004 ↗
24. 10.3390/ma1205077910.3390/ma12050779 ↗
25. 10.1039/D0BM00222D10.1039/D0BM00222D ↗
26. Dos Santos A. F. · J. Cancer Metastasis Treat. · 2019 · 5 · 10.20517
27. 10.1111/phpp.1248910.1111/phpp.12489 ↗
28. 10.1021/acsnano.8b0704510.1021/acsnano.8b07045 ↗
29. 10.1186/s40425-019-0826-310.1186/s40425-019-0826-3 ↗
30. 10.1039/C9CC08447A10.1039/C9CC08447A ↗
31. 10.1039/C9TB00630C10.1039/C9TB00630C ↗
32. 10.7150/thno.4607610.7150/thno.46076 ↗
33. 10.1016/j.cej.2019.12207910.1016/j.cej.2019.122079 ↗
34. 10.1021/acsami.8b2257910.1021/acsami.8b22579 ↗
35. 10.1371/journal.pone.006907310.1371/journal.pone.0069073 ↗
36. 10.2217/fon-2020-072010.2217/fon-2020-0720 ↗
37. 10.1016/j.jconrel.2019.05.03610.1016/j.jconrel.2019.05.036 ↗
38. 10.1038/ncomms1319310.1038/ncomms13193 ↗
39. 10.1021/acsnano.7b0071510.1021/acsnano.7b00715 ↗
40. 10.1016/j.biomaterials.2019.11962910.1016/j.biomaterials.2019.119629 ↗
41. 10.1002/adhm.20170007310.1002/adhm.201700073 ↗
42. 10.1016/j.jconrel.2020.03.04510.1016/j.jconrel.2020.03.045 ↗
43. 10.3390/cancers1112185510.3390/cancers11121855 ↗
44. 10.1186/s40580-019-0193-210.1186/s40580-019-0193-2 ↗
45. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
46. 10.1002/adhm.20190122310.1002/adhm.201901223 ↗
47. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
48. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
49. 10.1021/nn500211210.1021/nn5002112 ↗
50. 10.1038/s41392-019-0062-910.1038/s41392-019-0062-9 ↗
51. 10.1039/C9TB02238D10.1039/C9TB02238D ↗
52. 10.1016/j.jphotochemrev.2012.09.00410.1016/j.jphotochemrev.2012.09.004 ↗
53. Yang Z. · Mol. Med. Rep. · 2019 · 20 · 5
54. 10.1002/adhm.20190166510.1002/adhm.201901665 ↗
55. 10.1039/D0TB02378G10.1039/D0TB02378G ↗
56. 10.1016/j.ijpharm.2020.11934610.1016/j.ijpharm.2020.119346 ↗
57. 10.1021/acsami.8b1875110.1021/acsami.8b18751 ↗
58. 10.1016/j.jconrel.2019.01.02710.1016/j.jconrel.2019.01.027 ↗
59. 10.1002/adma.20190092710.1002/adma.201900927 ↗
60. 10.3389/fimmu.2013.0043810.3389/fimmu.2013.00438 ↗
61. 10.1021/acs.biomac.8b0046010.1021/acs.biomac.8b00460 ↗
62. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
63. 10.1038/nrc338010.1038/nrc3380 ↗
64. 10.1158/1078-0432.CCR-18-112610.1158/1078-0432.CCR-18-1126 ↗
65. 10.3389/fonc.2019.0119610.3389/fonc.2019.01196 ↗
66. 10.1002/advs.20180215710.1002/advs.201802157 ↗
67. 10.18632/oncotarget.597510.18632/oncotarget.5975 ↗
68. 10.1111/jcmm.1435610.1111/jcmm.14356 ↗
69. 10.1021/acsami.9b0354110.1021/acsami.9b03541 ↗
70. 10.1016/j.biomaterials.2018.05.05110.1016/j.biomaterials.2018.05.051 ↗
71. 10.1016/j.radonc.2008.05.01510.1016/j.radonc.2008.05.015 ↗
72. 10.1002/adtp.20200019110.1002/adtp.202000191 ↗
73. 10.1038/s41427-018-0091-910.1038/s41427-018-0091-9 ↗
74. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
75. 10.1021/acs.bioconjchem.8b0006810.1021/acs.bioconjchem.8b00068 ↗
76. 10.1021/acsnano.0c0561710.1021/acsnano.0c05617 ↗
77. 10.1016/j.canlet.2020.05.01110.1016/j.canlet.2020.05.011 ↗
78. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
79. Ke X. · Oncol. Lett. · 2019 · 18 · 5871
80. 10.1155/2016/205364610.1155/2016/2053646 ↗
81. 10.1016/j.apsb.2017.09.00510.1016/j.apsb.2017.09.005 ↗
82. 10.1016/j.jphotobiol.2020.11191310.1016/j.jphotobiol.2020.111913 ↗
83. 10.3322/caac.2011410.3322/caac.20114 ↗
84. 10.1038/nrc189410.1038/nrc1894 ↗
85. 10.1002/jcp.2949110.1002/jcp.29491 ↗
86. 10.1155/2018/462547210.1155/2018/4625472 ↗
87. 10.1186/s40425-015-0063-310.1186/s40425-015-0063-3 ↗
88. 10.1016/j.bbamcr.2014.05.01410.1016/j.bbamcr.2014.05.014 ↗
89. 10.1021/acsabm.8b0071810.1021/acsabm.8b00718 ↗
90. 10.1039/C8NR05323E10.1039/C8NR05323E ↗
91. 10.1021/acsnano.8b0020410.1021/acsnano.8b00204 ↗
92. 10.1016/j.biomaterials.2019.11937010.1016/j.biomaterials.2019.119370 ↗
93. 10.1021/acsami.8b0587610.1021/acsami.8b05876 ↗
94. 10.1039/C9NR09402D10.1039/C9NR09402D ↗
95. 10.1039/C9TB00089E10.1039/C9TB00089E ↗
96. 10.1016/j.tranon.2020.10082310.1016/j.tranon.2020.100823 ↗
97. 10.1186/s12943-019-1091-210.1186/s12943-019-1091-2 ↗
98. 10.1016/j.it.2018.10.00910.1016/j.it.2018.10.009 ↗
99. 10.1146/annurev-cancerbio-030419-03363510.1146/annurev-cancerbio-030419-033635 ↗
100. 10.4137/IJTR.S3835510.4137/IJTR.S38355 ↗